MODV vs. TERN, SPCE, CCCC, SNDL, HCAT, ACB, ERAS, ANIK, LXRX, and BMEA
Should you be buying ModivCare stock or one of its competitors? The main competitors of ModivCare include Terns Pharmaceuticals (TERN), Virgin Galactic (SPCE), C4 Therapeutics (CCCC), SNDL (SNDL), Health Catalyst (HCAT), Aurora Cannabis (ACB), Erasca (ERAS), Anika Therapeutics (ANIK), Lexicon Pharmaceuticals (LXRX), and Biomea Fusion (BMEA).
ModivCare (NASDAQ:MODV) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
98.3% of Terns Pharmaceuticals shares are held by institutional investors. 10.9% of ModivCare shares are held by insiders. Comparatively, 15.1% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, ModivCare had 2 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 4 mentions for ModivCare and 2 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.16 beat ModivCare's score of 0.90 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.
ModivCare has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.49, indicating that its share price is 149% less volatile than the S&P 500.
Terns Pharmaceuticals received 21 more outperform votes than ModivCare when rated by MarketBeat users. Likewise, 58.33% of users gave Terns Pharmaceuticals an outperform vote while only 40.00% of users gave ModivCare an outperform vote.
Terns Pharmaceuticals has lower revenue, but higher earnings than ModivCare. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than ModivCare, indicating that it is currently the more affordable of the two stocks.
ModivCare currently has a consensus price target of $49.25, indicating a potential upside of 78.64%. Terns Pharmaceuticals has a consensus price target of $14.94, indicating a potential upside of 142.10%. Given Terns Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Terns Pharmaceuticals is more favorable than ModivCare.
Terns Pharmaceuticals has a net margin of 0.00% compared to ModivCare's net margin of -8.02%. ModivCare's return on equity of 34.93% beat Terns Pharmaceuticals' return on equity.
Summary
Terns Pharmaceuticals beats ModivCare on 12 of the 18 factors compared between the two stocks.
Get ModivCare News Delivered to You Automatically
Sign up to receive the latest news and ratings for MODV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MODV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ModivCare Competitors List
Related Companies and Tools
